Novel therapies for multiple myeloma

Aging (Albany NY). 2017 Aug 28;9(8):1857-1858. doi: 10.18632/aging.101284.

Authors

Craig T Wallington-Beddoe^{1

2

3}, Stuart M Pitson^{1

3}

Affiliations

¹ Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.
² School of Medicine, The Flinders University of South Australia, Adelaide, Australia.
³ School of Medicine, The University of Adelaide, Adelaide, Australia.

No abstract available

Keywords: immunomodulatory agent; monoclonal antibody; myeloma; proteasome inhibitor; therapy.

Publication types

Editorial

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Immunologic Factors / therapeutic use*
Immunotherapy, Adoptive
Middle Aged
Multiple Myeloma / drug therapy*
Progression-Free Survival
Proteasome Inhibitors / therapeutic use*
Stem Cell Transplantation
Survival Rate
Treatment Outcome

Substances

Antibodies, Monoclonal
Immunologic Factors
Proteasome Inhibitors